PRODUCT INFORMATION



Plecanatide (acetate)

Item No. 33878

CAS Registry No.: 1075732-84-1

Formal Name: L-asparaginyl-L-α-aspartyl-L-α-glutamyl-

L-cysteinyl-L-α-glutamyl-L-leucyl-L-cysteinyl-L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl-Lthreonylglycyl-L-cysteinyl-L-leucine, cyclic $(4\rightarrow12)$, $(7\rightarrow15)$ -bis(disulfide),

monoacetate

SP-304 Synonym:

MF: $C_{65}H_{104}N_{18}O_{26}S_4 \bullet C_2H_4O_2$

FW: 1,741.9 **Purity:** λ_{max}: 259 nm UV/Vis.: Supplied as: A solid Storage: -20°C

Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Plecanatide (acetate) is supplied as a solid. A stock solution may be made by dissolving the plecanatide (acetate) in the solvent of choice, which should be purged with an inert gas. Plecanatide (acetate) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of plecanatide (acetate) in these solvents is approximately 3 and 1 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of plecanatide (acetate) can be prepared by directly dissolving the solid in aqueous buffers. The solubility of plecanatide (acetate) in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Plecanatide is a peptide agonist of the guanylate cyclase C receptor. It stimulates cGMP production in T84 colon cancer cells (EC₅₀ = 170 nM). Plecanatide (10 ppm in the diet) reduces increases in the number of neoplastic colon epithelial cells expressing Ki-67, a marker of cell proliferation, induced by dextran sulfate (DSS; Item No. 23250) in cancer-prone Apc^{+/Min-FCCC} mice.² It suppresses trinitrobenzenesulfonic acid-induced increases in abdominal contractions in a rat model of visceral hypersensitivity when administered at doses of 0.01 and 0.05 mg/kg.3 Formulations containing plecanatide have been used in the treatment of chronic idiopathic constipation.

References

- 1. Shailubhai, K., Palejwala, V., Arjunan, K.P., et al. World J. Gastrointest. Pharmacol. Ther. 6(4), 213-222
- 2. Chang, W.-C.L., Masih, S., Thadi, A., et al. World J. Gastrointest. Pharmacol. Ther. 8(1), 47-59 (2017).
- 3. Boulete, I.-M., Thai, A., Beaufrand, C., et al. World J. Gastroenterol. 24(17), 1888-1900 (2018).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 09/07/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM